期刊文献+

伴有高血压的颅内动脉粥样硬化性狭窄及相关性缺血性脑卒中的降血压治疗 被引量:8

The Intracranial Atherosclerotic Stenosis and Treatment of Ischemic Stroke
原文传递
导出
摘要 伴有高血压的颅内动脉粥样硬化性狭窄(ICAS)是降压治疗的适应证。制定目标血压值,除了要考虑ICAS患者的血压水平外,还要考虑其基础疾病以及年龄。目前没有统一的目标血压值。对ICAS相关性急性缺血性脑卒中(AIS)的高血压是否要降压,以及降压的最佳血压值,尚无统一意见。对过高的血压进行降压,以及避免过度降血压,是业内学者的共识。要根据患者的基础疾病决定降低血压幅度,对伴有高血压的ICAS相关性缺血性脑卒中患者,降压治疗能防止其复发。目前,还没有关于ICAS及其相关性缺血性脑卒中的血压管理标准。 Intracranial atherosclerotic stenosis (ICAS) with hypertension is a treatment indication.While the target blood pressure values were being set,not only the level of blood pressure of patients with ICAS but their pre-existing conditions and age were considered.There are no unified target blood pressure values.There are no standard of lowering blood pressure,as well as the best blood pressure step-down value,in hypertension caused by ICAS-related acute ischemic stroke (AIS).Lowering high blood pressure and avoiding excessive step-down are consensus.Blood pressure step-down value should be decided according to the patients' pre-existing conditions.For the patients with hypertension caused by ICAS-related ischemic stroke,antihypertensive therapy can prevent its recurrence.There are no hypertension management standards about ICAS and its related ischemic stroke.
作者 涂雪松
出处 《中国临床神经科学》 2014年第3期352-355,360,共5页 Chinese Journal of Clinical Neurosciences
关键词 颅内动脉粥样硬化 颅内动脉粥样硬化性狭窄 缺血性脑卒中 高血压 治疗 intracranial atherosclerosis intracranial atherosclerotic stenosis ischemic stroke hypertension treatment
  • 相关文献

参考文献2

二级参考文献101

  • 1秦俭(编译),赵妍(编译).胆固醇水平与出血性脑卒中发病的人群差别:血清胆固醇与出血性脑卒中、缺血性脑卒中及心肌梗死:韩国国家卫生系统前瞻性队列研究[J].世界急危重病医学杂志,2006,3(4):1397-1400. 被引量:45
  • 2Wahlgren N, Ahrced N, Davalos A, et al; SITS-MOST Investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITSMOST): an observational study. Lancet, 2007, 369: 275-282.
  • 3Lyden PD, ed. Thrombolytic Therapy for Acute Stroke. 2nd ed. Totowa, NJ: Hmreana Press, 2005.
  • 4Wardlaw JM, Smdercock PA, Berg: E. Throrrbolytic therapy with recoinbinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cunaflative meta-analysis. Stroke, 2003, 34: 1437-1442.
  • 5Wardlaw JM, Zoppo G, Yamaguchi T, et al. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev, 2003, (4): CD000213.
  • 6Shanna M, Clark H, Armour T, et al. Acute stroke: evaluation and treatment. Evid Rep Technol Assess (Sunmm), 2005, (127): 1-7.
  • 7Hill MD, Buchan AM; Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Throrrbolysis for acute ischemic stroke: results of the Canadian Altephse for Stroke Effectiveness Study. CMAJ, 20(0, 172: 1307-1312.
  • 8Chung H, Refoios Canto R, Canto RR, et al. Alteplase for the treatment of acute ischaemic stroke: NICE technology appraisal guidance. Heart, 2007, 93: 1616-1617.
  • 9Saver JL, Smith EE, Fonarow GC, et al; GWTG-stroke Steering Committee and Investigators. The "golden hour" and acute brain ischemia: presenting features and lytic therapy in > 30,000 patients ariving within 60 minutes of stroke onset. Stroke, 2010, 41: 1431-1439.
  • 10Scott PA, Xu Z, Meurer WJ, et al. Attitudes and beliefs of Michigan emergmcy physicians toward tissue plasminogen activator use in stroke: baseline survey results from the INcreasing Stroke Treatment through INteractive behavioral Change Tactic (INSTINCT) trial hospitals. Stroke, 2010, 41: 2026-2032.

共引文献1404

同被引文献55

引证文献8

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部